Studie - Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016

Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, 'Acute Heart Failure — Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acute heart failure market. The report identifies the key trends shaping and driving the global acute heart failure market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global acute heart failure sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global acute heart failure market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global acute heart failure market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with acute heart failure.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global acute heart failure market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acute heart failure market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global acute heart failure market landscape? — Identify, understand and capitalize.

Companies mentioned:
Novartis AG
Biogen Idec
Bayer AG

PRESS RELEASE
Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, 'Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acute heart failure market (AHF). The report identifies the key trends shaping and driving the market, and provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the AHF sector.

The Acute Heart Failure Market is Forecast to Show Slow Growth Until 2016

GlobalData predicts the AHF therapeutics market to be valued at $2.3 billion in 2009. The market is estimated to grow up to $2.6 billion in 2016, with a CAGR of 2.1%. Growth in the AHF market is driven by the increasing number of patients and the launch of new promising drugs during the next few years. The US is the largest market for AHF and it contributes to approximately 50% of the global market.

The Acute Heart Failure Market Has High Unmet Need In Terms Of Efficacy

The current AHF market is underserved by the existing treatment options. GlobalData’s analysis revealed that the current unmet need in the AHF market is approximately 58%. A major reason for this is attributed to the low efficacy aspects of the available treatment options. The value of unmet need in 2009 was calculated to be $1.3 billion. This suggests that there is huge untapped potential in the current AHF market. And this could be captured by novel molecules, targeted to fulfill the current void left by the existing treatment options. Thus the AHF market has high potential for further research and development activities.

Opportunity and Unmet Need in the Acute Heart Failure Market, 2010

Source: GlobalData

The Acute Heart Failure Market Growth is Driven By Increasing Number of Patients and Launch of New Treatment Options in The Next Few Years

Elderly people are at greater risk of developing AHF. More than half of the current patient population for AHF includes people aged over 50. A UN study of the global aging population reveals that the growth rate for the elderly population (1.9%) is significantly higher than the growth rate for the total population (1.2%). Thus an increase in the incidence for AHF could be expected in the next few decades.

There are limited treatment options for the treatment of AHF. Existing therapies are dominated by generic drugs. Even though the present developmental pipeline for AHF is relatively weak in terms of the number of molecules, there exist promising molecules in both the Phase II and III stages of the pipeline. These molecules comprise of both first-in-class mechanisms of action and existing mechanisms of action (me-toos) and this is likely to address the void left by the current therapeutic options in terms of both safety and efficacy. Hence positive outcomes for these developmental drugs will cause a shift in the prescription trend, switching the therapeutic options from current generic drugs to the new upcoming drugs with innovative mechanism of action.

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Acute Heart Failure: Market Characterization 5

2.1 Overview 5

2.2 Acute Heart Failure Market Size 5

2.3 Acute Heart Failure Market Forecast and CAGR 6

2.4 Drivers and Barriers for the AHF Market 8

2.4.1 Drivers of the Acute Heart Failure Market 8

2.4.2 Barriers for the Acute Heart Failure Market 8

2.5 Opportunity and Unmet Need 9

2.6 Key Takeaway 10

3 Acute Heart Failure Market: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Profile for the Major Marketed Products in the Acute Heart Failure Market 12

3.3.1 Natrecor (Nesiritide) 12

3.3.2 Primacor (Milrinone Lactate) 12

3.3.3 Coreg (Carvedilol) 13

3.3.4 Altace (Ramipril) 14

3.3.5 Atacand (Candesartan) 15

3.3.6 Bidil (Isosorbide Dinitrate and Hydralazine Hydrochloride) 16

3.4 Key Takeaway 17

4 Acute Heart Failure: Pipeline Assessment 18

4.1 Overview 18

4.2 Strategic Pipeline Assessment 18

4.2.1 Technology Trends Analytic Framework 18

4.3 Acute Heart Failure Therapeutics — Promising Drugs under Clinical Development 19

4.4 Drugs under Clinical Development 20

4.4.1 Tekturna/Rasilez 20

4.4.2 Lixivaptan 20

4.4.3 Relaxin 21

4.4.4 Cinaciguat 22

4.5 Acute Heart Failure Therapeutics Market — Clinical Pipeline by Mechanism of Action 22

4.6 Acute Heart Failure Pipeline — Pipeline by Clinical Phases of Development 23

4.6.1 Acute Heart Failure Therapeutics — Phase III Clinical Pipeline 23

4.6.2 Acute Heart Failure Therapeutics — Phase II Clinical Pipeline 24

4.6.3 Acute Heart Failure Therapeutics — Phase I Clinical Pipeline 24

4.7 Discontinued / Suspended Drugs for Acute Heart Failure 24

4.8 Key Takeaway 24

5 Acute Heart Failure Market: Implications for Future Market Competition 25

6 Acute Heart Failure Market: Future Players in the Acute Heart Failure Market 26

6.1 Introduction 26

6.2 Novartis AG 26

6.2.1 Overview 26

6.2.2 Business Description 27

6.2.3 Cardiovascular Portfolio 28

6.2.4 Acute Heart Failure Product Portfolio 28

6.3 Biogen Idec. 30

6.3.1 Overview 30

6.3.2 Business Description 30

6.3.3 Cardiovascular Portfolio 31

6.3.4 Acute Heart Failure Product Portfolio 31

6.4 Bayer AG 31

6.4.1 Overview 31

6.4.2 Business Description 32

6.4.3 Cardiovascular Portfolio 33

6.4.4 Acute Heart Failure product portfolio 33

7 Acute Heart Failure Market: Appendix 34

7.1 Definitions 34

7.2 Abbreviations 34

7.3 Research Methodology 35

7.3.1 Coverage 35

7.3.2 Secondary Research 36

7.3.3 Forecasting 36

7.3.4 Primary Research 39

7.3.5 Expert Panels 39

7.4 Contact Us 39

7.5 Disclaimer 39

7.6 Sources 40



1.1 List of Tables

Table 1: Global AHF Market Revenues ($m), 2001-2009 6

Table 2: Global AHF Market Revenues ($m), 2009-2016 7

Table 3: Major Marketed Product in the Acute Heart Failure Market, 2010 17

Table 4: Acute Heart Failure Therapeutics —Promising Drugs Under Clinical Development, 2010 19

Table 5: Acute Heart Failure Therapeutics — Phase III Clinical Pipeline, 2010 23

Table 6: Acute Heart Failure Therapeutics — Phase II Clinical Pipeline, 2010 24

Table 7: Acute Heart Failure Therapeutics — Phase I Clinical Pipeline, 2010 24

Table 8: List of Discontinued Drugs for Acute Heart Failure, 2010 24

Table 9: Novartis AG — Cardiovascular and Acute Heart Failure Pipeline, 2010 28

Table 10: Biogen Idec. — Cardiovascular and Acute Heart Failure Pipeline, 2010 31

Table 11: Bayer AG — Cardiovascular and Acute Heart Failure Pipeline, 2010 33



1.2 List of Figures

Figure 1: Global Acute Heart Failure Market Revenue ($m), 2001—2009 6

Figure 2: Global AHF Market Forecast ($m), 2009-2016 7

Figure 3: Opportunity and Unmet Need in the AHF Market, 2010 9

Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Acute Heart Failure, 2010 11

Figure 5: Technology Trends Analytic Framework of the Acute Heart Failure Pipeline, 2010 18

Figure 6: Technology Trends Analytic Framework of Acute Heart Failure Pipeline, Description, 2010 19

Figure 7: Acute Heart Failure Therapeutics Market — Clinical Pipeline by Mechanism of Action, 2010 23

Figure 8: Acute Heart Failure Pipeline by Phase of Clinical Development, 2010 23

Figure 9: Implications for Future Market Competition in the Acute Heart Failure Market, 2010 25

Figure 10: Acute Heart Failure Therapeutics Market — Clinical Pipeline by Company, 2010 26

Figure 11: GlobalData Methodology 35

Figure 12: GlobalData Market Forecasting Model 38

• Marktausblick bis 2015: Herz und Gefäß (kardiovaskulär)
• Analysis of Congenital Heart Diseases Market
• France Cardiovascular Devices Market Outlook to 2016
• Italy Cardiovascular Devices Market Outlook to 2016
• Australia Cardiovascular Devices Market Outlook to 2016
• Argentina Cardiovascular Devices Market Outlook to 2016
• Republic of Korea Cardiovascular Devices Market Outlook to 2016
• Taiwan Cardiovascular Devices Market Outlook to 2016
• India Cardiovascular Devices Market Outlook to 2016
• China Cardiovascular Devices Market Outlook to 2016
• Spain Cardiovascular Devices Market Outlook to 2016
• Netherlands Cardiovascular Devices Market Outlook to 2016
• Belgium Cardiovascular Devices Market Outlook to 2016
• United Kingdom Cardiovascular Devices Market Outlook to 2016
• Japan Cardiovascular Devices Market Outlook to 2016
• United States Cardiovascular Devices Market Outlook to 2016
• Germany Cardiovascular Devices Market Outlook to 2016
• Cough, Cold and Allergy (Hay Fever) Remedies - Malaysia
• Acute Coronary Syndromes Therapy Area Pipeline Report
• Atrial Fibrillation Therapy Area Pipeline Report